2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
Original-Research: Cardiol Therapeutics Inc. - von GBC AG
Einstufung von GBC AG zu Cardiol Therapeutics Inc.
Unternehmen: Cardiol Therapeutics Inc.
ISIN: CA14161Y2006
Anlass der Studie:
Empfehlung: International Investment Forum
Letzte Ratingänderung:
Analyst: Julien Desrosiers; Felix Haugg
Upcoming Investor Event:
Cardiol Therapeutics Inc. to present at digital International Investment
Forum (IIF)
On May 19, the IIF International Investment Forum will take place. At this forum, Cardiol Therapeutics Inc. will also present its business model and current business development.
Presentation slot:
Cardiol Therapeutics Inc. (ISIN: CA14161Y2006)
08.40 am EST (New York, Toronto time)
02.40 pm CEST (Frankfurt, Paris time)
08.40 pm HKT (Hong Kong, Perth, Singapore time)
Speaker: David Elsley, CEO
The International Investment Forum (IIF) is a live, digital-only event that provides access to publicly traded companies from the small- and mid-cap segments around the world. Speakers on May 19, 2022 will be board members of publicly traded companies from the technology, commodities, security, medical, logistics and aerospace sectors.
The program with schedule can be found at the following link:
https://ii-forum.com/timetable-all-events/
The registration for this event is available at the following link:
https://us06web.zoom.us/webinar/register/3716522695074/ WN_DGpMon9sSautfBEH4gZ8Ng
Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/24111.pdf
Kontakt für Rückfragen
GBC AG
Halderstraße 27
86150 Augsburg
0821 / 241133 0
research@gbc-ag.de
+++++++++++++++
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,7,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter:
http://www.gbc-ag.de/de/Offenlegung
+++++++++++++++
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
